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In search of a rational approach to 
chronic kidney disease detection 
and management
AJ Kallen1 and PR Patel1
Rates of incident end-stage renal disease persist above established 
goals, driving efforts for early identification of chronic kidney disease 
(CKD) to reduce progression. The detection of CKD using existing 
electronic data sources has been proposed as an efficient identification 
method; however, this method is not without potential challenges and 
limitations.
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Decreasing the morbidity and mortality 
associated with chronic kidney disease 
(CKD) and preventing its progression 
to end-stage renal disease (ESRD) have 
become key public-health objectives in 
the United States.1 Th e rate of incident 
ESRD in the United States rose from 289 
per million population in 1997 to a high 
of 343 per million population in 2003. 
Th e slightly lower incidence observed in 
2004 (339 per million population) is still 
far from the Healthy People 2010 goal 
of 217 cases per million population.1,2 It 
has also become apparent that a greater 
proportion of patients with CKD will die, 
oft en from cardiovascular disease, than 
will advance to ESRD.3  Perhaps most 
importantly, it may be possible to decrease 
the risk of both renal disease progression 
and cardiovascular events among persons 
with CKD. Use of angiotensin-convert-
ing enzyme inhibitors, aggressive blood 
pressure management, and tight glycemic 
control have all met with success for some 
patients in achieving one or both of these 
prevention goals.4
Recently published prevalence stud-
ies have begun to uncover the extent of 
CKD in developed countries. In a study of 
a large United Kingdom population con-
ducted by Stevens et al.5 (this issue), the 
age-adjusted prevalence of stage 3–5 CKD 
was 8.5%. Estimates based on the Th ird 
National Health and Nutrition Examina-
tion Survey (NHANES III) suggest that 
8.8% of the United States population have 
stage 1–4 CKD; approximately 7.7 million 
persons in the United States have stage 3 
or 4 CKD.6 Additionally, CKD appears to 
be unrecognized in a substantial propor-
tion of those with the disease. Stevens et 
al.5 note that only 1.6% of patients with 
a glomerular fi ltration rate (GFR) less 
than 60 ml per minute per 1.73 m2 had 
a diagnosis of renal disease recorded. In 
a United States study, fewer than 10% of 
individuals with CKD recalled being told 
of the diagnosis.6
The hope is that early identification 
of previously unrecognized CKD will 
facilitate interventions to delay death, 
improve quality of life, and postpone or 
prevent progression to ESRD. Although 
this seems a logical conclusion, it is not 
completely clear how it would best be 
accomplished. Th e ongoing debate sur-
rounding best practices for CKD iden-
tifi cation, management, and prevention 
was heightened recently in the wake of 
the Correction of Hemoglobin and Out-
comes in Renal Insuffi  ciency and Cardio-
vascular Risk Reduction by Early Anemia 
Treatment with Epoetin Beta (CREATE) 
trials.7,8 These studies suggested that 
complete correction of anemia off ers no 
advantage, and may actually cause harm, 
compared with partial anemia correction 
in patients with CKD. Although the stud-
ies addressed only one aspect of recom-
mended CKD management, they serve as 
a reminder that conventional wisdom is 
not always supported by evidence from 
randomized trials. Th e present challenge 
is to identify and implement a means 
of early CKD detection that will lead to 
improved outcomes, ideally at a reason-
able cost to society.
Several issues need to be considered 
in the discussion of early detection or 
screening programs, including the one 
proposed by Stevens et al. (Table 1).5 Th e 
fi rst consideration is the extent to which 
the test identifi es those at highest risk for 
adverse outcomes. In general, screening 
tests identify patients with true disease, 
but they also may identify patients with 
‘pseudodisease’. A person with pseudodis-
ease is identifi ed as ‘diseased’ by screening; 
however, the condition, if left  untreated, 
will never aff ect the person’s life, either 
because he or she will die of an unrelated 
cause or because the disease will not 
progress. Th ese patients could potentially 
be harmed by screening if invasive tests 
are performed or treatments are adminis-
tered as a result of the positive screening 
test. Th is may be particularly true in the 
elderly, the group with the highest preva-
lence of CKD2 and for whom preventive 
therapies may be less likely to improve 
survival or quality of life. In contrast to 
general-population screening, strategies 
that target a subset of higher-risk indi-
viduals would be expected to yield fewer 
false-positive tests and detect less pseudo-
disease. Further investigation is needed to 
clarify the level of renal dysfunction that 
distinguishes those who are at higher risk 
for adverse outcomes and most likely to 
benefi t from interventions from those 
who are not.
Issues may also exist with regard to the 
characteristics of the test itself. Estimated 
GFR values have advantages over simple 
measurements of serum creatinine, but 
the methods used to calculate GFR are 
not perfect. Th e advantages of the Modi-
fi cation of Diet in Renal Disease study 
(MDRD) equation for GFR are that it is 
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relatively noninvasive and inexpensive 
when compared with other detection 
methods. However, the MDRD formula 
has not been validated in some popula-
tions, including the elderly and persons 
with CKD risk factors but normal kidney 
function — groups for which misclassifi -
cation and pseudodisease are particular 
concerns.9 Widespread implementation 
of the MDRD method is also problematic 
in settings where creatinine calibration 
cannot be achieved.10 Additional stud-
ies should be conducted to determine 
the test’s performance in representative 
populations.
A fundamental question is whether 
generalized screening for CKD adds sig-
nifi cantly to the targeted screening and 
treatment recommendations that are cur-
rently in place. In 2004, approximately 
91% of United States Medicare patients 
diagnosed with CKD had diabetes and/or 
hypertension, and these two conditions 
accounted for 71% of new ESRD cases.1 
Whether enhancing or further refi ning 
screening among these and other high-
risk populations could improve renal 
disease outcomes without broader popu-
lation initiatives merits consideration.
A related issue is whether systems are 
in place to provide the necessary care 
to those who have been identifi ed as at 
risk. Stevens et al.5 demonstrated that 
providers in a primary-care practice 
failed to achieve target blood pressure 
(< 130/80 mm Hg) in stage 3–5 CKD 
patients with hypertension 90% of the 
time and achieved blood pressure of less 
than 150/90 mm Hg in only 54% of these 
patients. Among stage 3–5 CKD patients 
with diabetes, 41% had elevated glyco-
sylated hemoglobin levels (hemoglobin 
A1c > 7.5%).5 Th e failure to meet recog-
nized goals for diabetes and hyperten-
sion management suggests systematic 
problems with implementation of pre-
vention strategies that may limit the util-
ity of additional screening for CKD.
Th e potential impact of newly identi-
fi ed patients on the health-care system 
should also be considered, particularly 
given the estimated burden of unrecog-
nized CKD. Realistic solutions would be 
needed to manage these patients, without 
further fragmentation of care between 
primary-care providers and renal spe-
cialists. It has been suggested that the 
projected infl ux of newly identifi ed CKD 
patients would exceed the capacity and 
availability of specialists to solely man-
age their disease.10 Eff orts to improve 
management should be directed toward 
primary-care physicians, who provide 
the bulk of the care to these patients. 
Educational and quality-improvement 
initiatives would need to be established 
and continually evaluated to ensure they 
have the desired effect of optimizing 
CKD treatment. Primary-care providers 
should be considered equal stakeholders 
in these eff orts and should be actively 
engaged in guideline development and 
identification of CKD best practices. 
Partnering with these fi rst-line care pro-
viders seems essential to the success of 
any pre-ESRD CKD initiatives.
Lastly, are eff orts to reduce the com-
plications of CKD focused on the appro-
priate level of prevention? Would more 
people be better served if eff orts were 
concentrated ‘upstream’ on primary pre-
vention of renal disease risk factors before 
the development of CKD? Although such 
interventions are frequently challenging, 
prevention eff orts aimed at reducing new 
cases of diabetes, hypertension, and obes-
ity may do more to decrease the burden 
of ESRD and the costs of providing renal 
replacement therapy than the best CKD 
management.
How do we reconcile these unan-
swered questions with the simultaneous 
call to action to stem the tide of CKD 
progression and associated adverse 
events? Stevens et al.5 present one option 
by demonstrating that preexisting elec-
tronic data can be used to identify 
patients with CKD within large primary-
care populations without the added cost 
of a separate screening program. A sig-
nifi cant limitation to this approach is 
the fact that only 32% of adults in the 
primary-care practices studied had their 
serum creatinine levels recorded to allow 
for GFR evaluation.5 Whether untested 
patients excluded from the study sample 
were at greater risk for CKD is unknown. 
Th is approach to CKD identifi cation, 
although convenient, remains subject to 
many of the same challenges and unre-
solved issues that exist for other screen-
ing methods.
A successful CKD screening initiative 
must not only recognize CKD patients 
Table 1 | Challenges and unresolved issues surrounding chronic kidney disease 
screening
Issue Questions
Population at risk Who should be screened?
Should targeted or more generalized screening be conducted?
What level of GFR identifies people at risk?
Imperfect test Is GFR measurement reliable and fully validated?
Is use of a confirmatory test warranted for some patients?
Existing screening programs Would improvement of existing targeted screening and 
prevention programs (i.e., for patients with diabetes and 
hypertension) provide a better solution than generalized 
screening?
Health-care access/quality Do existing challenges to health-care access limit the benefits 
for screening?
How should disease management for patients identified with 
CKD be improved?
Provider roles and health-care 
capacity
How will health-care systems provide care for the volume of 
newly identified patients?
What aspects of CKD patient care should be managed by 
primary providers vs. specialists?
Impact of interventions How successful are efforts to prevent new cases of CKD as 
compared with treatment of identified cases in terms of 
reducing adverse outcomes?
Are interventions in certain population subgroups (e.g., elderly 
patients) beneficial?
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate.
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but also clarify and disseminate infor-
mation on best practices, and ensure that 
the health-care system has the capacity 
to meet the evolving needs of patients 
once they are identifi ed. We must have 
reliable tests that accurately discern at-
risk populations, evidence-based strate-
gies that truly decrease the occurrence of 
adverse outcomes in these patients, and 
the ability to implement these strategies 
eff ectively. Th e fi ndings of Stevens and 
his colleagues5 will help to inform the 
discussion surrounding CKD identifi ca-
tion and management — particularly as 
further data on outcomes from this and 
similar initiatives become available in 
the future.
DISCLAIMER 
The findings and conclusions in this report are 
those of the authors and do not necessarily 
represent the views of the Centers for Disease 
Control and Prevention.
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Tumor necrosis factor-α in 
cisplatin nephrotoxicity: 
A homebred foe?
Z Dong1 and SS Atherton1
A robust inflammatory response involving tumor necrosis factor-α 
(TNF-α) is induced during cisplatin nephrotoxicity. Using chimeric 
models, Reeves and colleagues now demonstrate that resident kidney 
cells, rather than infiltrating immune cells, are the major producers 
of TNF-α. Blockade of TNF-α attenuates inflammation and associated 
kidney injury.
Kidney International (2007) 72 5–7. doi:10.1038/sj.ki.5002320 
1Department of Cellular Biology and Anatomy, 
Medical College of Georgia and Veterans Affairs 
Medical Center, Augusta, Georgia, USA
Correspondence: Z Dong, Department of Cellular 
Biology and Anatomy, Medical College of Georgia, 
1459 Laney Walker Boulevard, Augusta, Georgia 
30912, USA. 
E-mail: zdong@mail.mcg.edu
Cisplatin, a widely used chemothera-
peutic agent, is used to treat a variety of 
cancers. A major drawback of this drug is 
its side eff ects in normal cells and tissues, 
prominently toxicity in the kidneys. Over 
30% of patients develop renal problems 
during cisplatin treatment, which limits 
the use and effi  cacy of cisplatin in can-
cer therapy. Th e cellular and molecular 
mechanism of cisplatin nephrotoxicity 
is a topic of intense investigation, is very 
complex, and involves multiple factors 
and processes, including a robust infl am-
matory response and, ultimately, death of 
renal tubular cells.1
Tumor necrosis factor-α (TNF-α) is a 
key player in the infl ammatory response 
during cisplatin nephrotoxicity. TNF-α 
production was induced under the 
pathological condition.2–4 Importantly, 
in TNF-α-deficient mice, the produc-
tion and secretion of proinfl ammatory 
cytokines and chemokines were attenu-
ated, and this was associated with amel-
ioration of acute kidney injury and renal 
failure during cisplatin treatment. Simi-
lar observations were shown for TNF-α 
inhibition by pharmacological inhibitors 
and neutralizing antibodies.3 Together, 
these studies have demonstrated a critical 
role for TNF-α in mounting the infl am-
matory response during cisplatin neph-
rotoxicity and the ensuing kidney tissue 
damage and acute renal failure.
Given the role of TNF-α in cisplatin 
nephrotoxicity, several important ques-
tions remain. How does cisplatin induce 
TNF-α expression? Where is TNF-α 
produced and by what cells? How does 
TNF-α stimulate the proinfl ammatory 
response? By what mechanism does 
TNF-α induce kidney injury and renal 
failure? Reeves and colleagues5 (this 
issue) have now provided significant 
insights into these important questions. 
Specifi cally, they have demonstrated that 
resident cells of the kidneys, rather than 
infi ltrating infl ammatory cells, are the 
major contributors of TNF-α production 
during cisplatin nephrotoxicity.5
When considering cytokine and chem-
okine production under pathological 
conditions, many of us tend to think 
about an origin from cells of the immune 
system. However, in the kidney, there 
are a variety of cells that can effi  ciently 
produce and secrete cytokines and 
chemokines. For example, production 
of TNF-α has been shown in mesangial 
cells, glomerular cells, endothelial cells, 
and renal tubular cells. So, is TNF-α 
produced by infi ltrating immune cells 
or parenchymal cells of the kidneys? 
To address this question, Reeves and 
see original article on page 37
